Population pharmacokinetic and exposure-response analyses for efficacy and safety of risankizumab in subjects with active Crohn's disease

被引：0
|
作者：
Suleiman, A. [1 ]
Goebel, A. [1 ]
Bhatnagar, S. [2 ]
D'Cunha, R. [2 ]
Liu, W. [2 ]
Pang, Y. [2 ]
机构：
[1] Clin Pharmacol & Pharmacometr, AbbVie, Ludwigshafen, Germany
[2] Clin Pharmacol & Pharmacometr, AbbVie, N Chicago, IL USA
来源：
JOURNAL OF CROHNS & COLITIS | 2022年 / 16卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P574
引用
收藏
页码：I514 / I516
页数：4
相关论文
共 50 条
  • [1] Population pharmacokinetic and exposure-response analyses for efficacy and safety of risankizumab in subjects with active Crohn's disease
    Suleiman, A.
    Goebel, A.
    Bhatnagar, S.
    D'Cunha, R.
    Liu, W.
    Pang, Y.
    JOURNAL OF CROHNS & COLITIS, 2022, 16 : I514 - I516
  • [2] Population Pharmacokinetic and Exposure-Response Analyses for Efficacy and Safety of Risankizumab in Patients With Active Crohn's Disease
    Suleiman, Ahmed Abbas
    Goebel, Aline
    Bhatnagar, Sumit
    D'Cunha, Ronilda
    Liu, Wei
    Pang, Yinuo
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2023, 113 (04) : 839 - 850
  • [3] Population pharmacokinetic and exposure-response analyses for efficacy and safety of risankizumab in subjects with moderately to severely active Ulcerative Colitis
    Thakre, N.
    Goebel, A.
    D'Cunha, R.
    Winzenborg, I.
    Liu, W.
    Pang, Y.
    JOURNAL OF CROHNS & COLITIS, 2024, 18 : I1831 - I1831
  • [4] Population Pharmacokinetic and Exposure-Response Analyses of Apremilast in Subjects with Active Psoriatic Arthritis
    Liu, Yong
    Kassir, Nastya
    Mouksassi, Samer
    Zhou, Simon
    Marier, Jean-Francois
    Palmisano, Maria
    JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2013, 40 : S34 - S35
  • [5] Exposure-Response Relationships for the Efficacy and Safety of Risankizumab in Japanese Subjects with Psoriasis
    Suleiman, Ahmed A.
    Khatri, Amit
    Oberoi, Rajneet K.
    Othman, Ahmed A.
    CLINICAL PHARMACOKINETICS, 2020, 59 (05) : 575 - 589
  • [6] UPADACITINIB PHARMACOKINETIC AND EXPOSURE-RESPONSE RELATIONSHIPS IN SUBJECTS WITH CROHN'S DISEASE - ANALYSES OF PHASE 3 STUDIES
    Bhatnagar, Sumit
    Schlacter, Louisa
    Eckert, Doerthe
    Stodtmann, Sven
    Liu, Wei
    Lacerda, Ana P.
    Mohamed, Mohamed-Eslam F.
    GASTROENTEROLOGY, 2023, 164 (06) : S1100 - S1101
  • [7] Population Pharmacokinetics and Exposure-Response Analyses for Risankizumab in Patients with Active Psoriatic Arthritis
    Thakre, Neha
    D'Cunha, Ronilda
    Goebel, Aline
    Liu, Wei
    Pang, Yinuo
    Suleiman, Ahmed A.
    RHEUMATOLOGY AND THERAPY, 2022, 9 (06) : 1587 - 1603
  • [8] Population Pharmacokinetics and Exposure-Response Analyses of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease
    Adedokun, Omoniyi J.
    Xu, Zhenhua
    Gasink, Christopher
    Kowalski, Ken
    Sandborn, William J.
    Feagan, Brian
    CLINICAL THERAPEUTICS, 2022, 44 (10) : 1336 - 1355
  • [9] UPADACITINIB EXPOSURE-RESPONSE RELATIONSHIPS FOR EFFICACY IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE - ANALYSIS OF CELEST STUDY
    Mohamed, Mohamed-Eslam F.
    Kluender, Ben
    Lacerda, Ana P.
    Othman, Ahmed A.
    GASTROENTEROLOGY, 2018, 154 (06) : S386 - S386
  • [10] POPULATION PK AND EXPOSURE-RESPONSE ANALYSES OF APREMILAST IN SUBJECTS WITH ACTIVE PSORIATIC ARTHRITIS
    Kassir, N.
    Savant, I.
    Mouksassi, M. S.
    Marier, J. F.
    Zhu, W.
    Lau, H.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2011, 89 : S90 - S90
12345